TFF Pharmaceuticals (MUN:0K30) - Stock Price, News & Analysis

0K30 Stock Overview

A clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. More details

0K30 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Earnings have grown 6% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Has less than 1 year of cash runway

Does not have a meaningful market cap (€1M)

Shareholders have been diluted in the past year

+ 1 more risk

TFF Pharmaceuticals, Inc. Competitors

Valeo Pharma

DB:VP2

€493.4k

MPH Health Care

DB:93M1

€103.6m

Biofrontera

XTRA:B8FK

€16.7m

SynBiotic

DUSE:SBX

€27.9m

Price History & Performance

Summary of all time highs, changes and price drops for TFF Pharmaceuticals
Historical stock prices
Current Share Price	US$2.18
52 Week High	US$8.00
52 Week Low	US$1.42
Beta	1.32
11 Month Change	6.86%
3 Month Change	-2.68%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-67.01%

Recent updates

Shareholder Returns

	0K30	DE Pharmaceuticals	DE Market
7D	0%	-5.0%	-1.3%
1Y	n/a	-22.0%	7.4%

Return vs Industry: Insufficient data to determine how 0K30 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 0K30 performed against the German Market.

Price Volatility

Is 0K30's price volatile compared to industry and market?
0K30 volatility
0K30 Average Weekly Movement	13.6%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 0K30's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 0K30's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2018	19	Craig Jalbert	tffpharma.com

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.

TFF Pharmaceuticals, Inc. Fundamentals Summary

How do TFF Pharmaceuticals's earnings and revenue compare to its market cap?
0K30 fundamental statistics
Market cap	€1.22m
Earnings (TTM)	-€17.56m
Revenue (TTM)	€1.10m

1.1x

P/S Ratio

-0.1x

P/E Ratio

Is 0K30 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0K30 income statement (TTM)
Revenue	US$1.16m
Cost of Revenue	US$11.97m
Gross Profit	-US$10.81m
Other Expenses	US$7.71m
Earnings	-US$18.52m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-5.34
Gross Margin	-931.02%
Net Profit Margin	-1,595.04%
Debt/Equity Ratio	0%

How did 0K30 perform over the long term?

See historical performance and comparison

TFF Pharmaceuticals MUN:0K30 Stock Report